Comparative Pharmacology
Head-to-head clinical analysis: ESTARYLLA versus KIMIDESS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ESTARYLLA versus KIMIDESS.
ESTARYLLA vs KIMIDESS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Estarylla is a combination oral contraceptive containing ethinyl estradiol and norgestimate. It suppresses gonadotropin release (FSH and LH) via estrogen and progestin, inhibiting ovulation. Additionally, it increases cervical mucus viscosity and alters endometrial receptivity, impeding sperm penetration and implantation.
KIMIDESS (ketoconazole) is an imidazole antifungal agent that inhibits the synthesis of ergosterol, a key component of fungal cell membranes, by inhibiting the cytochrome P450 enzyme lanosterol 14-alpha-demethylase.
One tablet (0.02 mg ethinyl estradiol and 0.15 mg desogestrel) orally once daily for 21 days, followed by 7 days of placebo. Hormone-free interval of 7 days.
5 mg orally once daily, with or without food.
None Documented
None Documented
Terminal elimination half-life of ethinyl estradiol is approximately 13-16 hours; clinical context: steady-state achieved within 5-7 days
Terminal elimination half-life is 14 hours (range 10-18 h); supports twice-daily dosing in most patients.
Renal: ~55% as metabolites, ~27% unchanged; Fecal: ~45% as metabolites
Renal excretion of unchanged drug accounts for approximately 40% of the administered dose; biliary/fecal elimination accounts for 50%, with the remainder undergoing metabolic clearance.
Category C
Category C
Combined Oral Contraceptive
Combined Oral Contraceptive